房颤合并既往缺血性卒中患者口服抗凝药安全性与疗效的网络荟萃分析
与华法林相比,阿哌沙班是唯一显著降低任何卒中和major bleeding的药物,艾多沙班是唯一显著降低心血管死亡和全因死亡的药物,但DOAC之间仅间接比较未发现差异。
要点
- 阿哌沙班较华法林显著降低任何卒中(RR 0.72)和major bleeding(RR 0.73)。
- 达比加群、阿哌沙班和艾多沙班较华法林显著降低出血性卒中和颅内出血,利伐沙班未达显著。
- 艾多沙班较华法林显著降低心血管死亡(RR 0.79)和全因死亡(RR 0.84)。
核心结论
- 在房颤合并既往缺血性卒中患者中,各DOAC相对华法林降低颅内和系统性出血,但并非所有药物均一致。
- 阿哌沙班是唯一较华法林显著降低任何卒中和major bleeding的药物。
- 由于试验数量少,仅基于间接比较,未能确立各DOAC之间的差异。
研究设计与样本
- 系统综述与频率学派随机效应网络荟萃分析,纳入房颤合并既往缺血性卒中或短暂性脑缺血发作的随机对照试验。
- 检索MEDLINE、Scopus和ClinicalTrials.gov,从建库至2026年5月。
主要发现
- 与华法林相比,阿哌沙班显著降低任何卒中(RR 0.72 [95% CI 0.53–0.97])和major bleeding(RR 0.73 [95% CI 0.54–0.99])。
- 达比加群、阿哌沙班和艾多沙班较华法林显著降低出血性卒中和颅内出血,利伐沙班在任何出血结局均未达显著。
- 艾多沙班是唯一与显著较低心血管死亡(RR 0.79 [95% CI 0.65–0.97])和全因死亡(RR 0.84 [95% CI 0.72–0.99])相关的药物。
- 所有DOAC之间的比较均为间接比较,未观察到个体DOAC之间的差异。
关键数值与推荐
- 主要结局为任何卒中;次要结局包括缺血性卒中、出血性卒中、major bleeding、颅内出血、心血管死亡和全因死亡。
- 治疗效果以风险比(RR)及95% CI表示。
临床怎么用
- 对于房颤合并既往缺血性卒中患者,选用DOAC时需权衡卒中复发与出血风险,阿哌沙班在降低任何卒中和major bleeding方面有显著证据。
- 艾多沙班在降低心血管死亡和全因死亡方面有显著证据,可结合患者个体情况考虑。
- 由于缺乏DOAC之间直接比较的证据,药物选择应基于间接比较结果和患者特征个体化决策。
局限性
- 证据网络为星形结构,每种DOAC仅由单一华法林对照试验提供证据,所有DOAC之间比较均为间接比较。
- 试验数量少,无法确立个体DOAC之间的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:Patients with atrial fibrillation (AF) and prior ischemic stroke represent a high-risk population facing competing risks of recurrent thromboembolism and hemorrhagic complications. Although direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists for stroke prevention in AF, no randomized controlled clinical trial has directly compared individual DOACs to each other in this population.METHODS:We conducted a systematic review and frequentist random-effects network meta-analysis of randomized-controlled clinical trials enrolling patients with AF and prior ischemic stroke or transient ischemic attack. MEDLINE, Scopus, and ClinicalTrials.gov were searched from inception until May 2026. The primary outcome was any stroke. Secondary outcomes included ischemic stroke, hemorrhagic stroke, major bleeding, intracranial hemorrhage (ICH), cardiovascular mortality, and all-cause mortality. Treatment effects were expressed as risk ratios (RR) with 95% CIs.RESULTS:The evidence network comprised 6 trials (18 395 patients) in a star-shaped structure. Each DOAC was informed by a single warfarin-controlled trial, and 2 trials used aspirin as the comparator. All between-DOAC comparisons were indirect. In the network meta-analysis, compared with warfarin, apixaban was the only agent to significantly reduce both any stroke (RR, 0.72 [95% CI, 0.53–0.97]) and major bleeding (RR, 0.73 [95% CI, 0.54–0.99]). Dabigatran, apixaban, and edoxaban each significantly reduced hemorrhagic stroke and ICH versus warfarin, whereas rivaroxaban did not reach significance for any bleeding outcome. Edoxaban was the only agent associated with significantly lower cardiovascular (RR, 0.79 [95% CI, 0.65–0.97]) and all-cause mortality (RR, 0.84 [95% CI, 0.72–0.99]). Based on indirect comparisons only, no differences between individual DOACs were observed.CONCLUSIONS:In patients with AF and prior ischemic stroke, individual DOACs reduced intracranial and systemic bleeding relative to warfarin, although not uniformly across agents. Apixaban alone significantly reduced both any stroke and major bleeding versus warfarin, but differences between individual DOACs could not be established given the small number of trials.REGISTRATION:URL:https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261404062.
引用
- Stroke:Comparative Safety and Efficacy of Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Ischemic Stroke: A Systematic Review and Network Meta-Analysis of Randomized-Controlled Clinical Trials
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。